trial

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

NCTId NCT03900754
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 26 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2024-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
26 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-01-13
Primary completion
2024-01-31
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

VA Office of Research and DevelopmentLead Sponsor
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator
VA Greater Los Angeles Healthcare SystemCollaborator

Investigators

1
Josh Woolley, BSPrincipal Investigator

Sites

2 total
San Francisco, United StatesWest Los Angeles, United States

Linked catalysts

1
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Respon — primary completion2024-01-31

Facts & assertions

4 sourced
Enrollment
26
Phase
PHASE2
Primary Completion Date
2024-01-31
Status
TERMINATED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
VA Office of Research and Development
company
collaborator
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
VA Greater Los Angeles Healthcare System
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Josh Woolley, BS
person